BNTC Benitec Biopharma Inc.

Nasdaq benitec.com


$ 13.12 $ 0.01 (0.08 %)    

Friday, 14-Nov-2025 15:54:19 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 13.16
$ 13.02
$ 13.09 x 52
$ 13.13 x 5
$ 12.75 - $ 13.26
$ 9.10 - $ 17.15
226,249
na
445.63M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 09-22-2025 06-30-2025 10-K
3 05-14-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-Q
5 11-14-2024 09-30-2024 10-Q
6 09-26-2024 06-30-2024 10-K
7 05-13-2024 03-31-2024 10-Q
8 02-13-2024 12-31-2023 10-Q
9 11-13-2023 09-30-2023 10-Q
10 09-21-2023 06-30-2023 10-K
11 05-15-2023 03-31-2023 10-Q
12 02-13-2023 12-31-2022 10-Q
13 11-10-2022 09-30-2022 10-Q
14 09-02-2022 06-30-2022 10-K
15 05-16-2022 03-31-2022 10-Q
16 02-14-2022 12-31-2021 10-Q
17 11-15-2021 09-30-2021 10-Q
18 09-20-2021 06-30-2021 10-K
19 05-12-2021 03-31-2021 10-Q
20 02-09-2021 12-31-2020 10-Q
21 11-13-2020 09-30-2020 10-Q
22 09-23-2020 06-30-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 benitec-biopharma-announces-underwritten-common-stock-offering-terms-not-disclosed

Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biot...

 hc-wainwright--co-maintains-buy-on-benitec-biopharma-raises-price-target-to-35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma (NASDAQ:BNTC) with a Buy and raises the price...

 citizens-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-22

Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the price tar...

 benitec-biopharma-provides-interim-clinical-results-for-bb-301-phase-1b2a-clinical-trial-following-administration-of-bb-301-cohort-1-patients-showed-significant-sustained-improvements-across-multiple-clinical-measures

Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechn...

 jmp-securities-reiterates-market-outperform-on-benitec-biopharma-maintains-20-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $20...

 benitec-biopharma-files-for-mixed-shelf-offering-of-up-to-200m

-SEC Filing

 correction-benitec-biopharma-q4-eps-042-misses-033-estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...

 oppenheimer-maintains-outperform-on-benitec-biopharma-lowers-price-target-to-29

Oppenheimer analyst Andreas Argyrides maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and lowers the price targe...

 benitec-biopharma-receives-green-light-to-advance-bb-301-trial-after-safety-review-cohort-2-enrollment-set-for-q4-2025

-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinic...

 hc-wainwright--co-reiterates-buy-on-benitec-biopharma-maintains-28-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:BNTC) with a Buy and maintains $28 p...

 jmp-securities-reiterates-market-outperform-on-benitec-biopharma-maintains-20-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $20...

 benitec-biopharma-q3-eps-024-beats-035-estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0...

 jmp-securities-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-20

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...

 hc-wainwright--co-reiterates-buy-on-benitec-biopharma-maintains-28-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:BNTC) with a Buy and maintains $28 p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION